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Synthesis of Some Imidazo[1,2-a]pyrazine Derivatives and Evaluation 
of Their Antinociceptive Activity
Bazı İmidazo[1,2-a]pirazin Türevlerinin Sentezi ve Antinosiseptif 
Aktivitelerinin Değerlendirilmeleri
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Amaç: İmidazopirazin halkası biyolojik olarak aktif bir heterosiklik halkadır. 
Bir dizi hidrazid-hidrazon türevi bileşiğin antibakteryial-antifungal, anti-
konvülzan, antiinflamatuvar, antitüberkülotik ve analjezik aktiviteye sahip 
olduğu belirtilmiştir. Aroilhidrazid-hidrazon yapısını içeren piridin, indol, 
imidazo [2,1-b]piridin ve imidazo[1,2-a]pirazin gibi hetero halkalar özel ilgi 
çekmektedir. N-(4-Sübstitüe benziliden)imidazo[1,2-a]pirazin-2-karbohid-
razit (2a-j) türevi bileşikler daha önce belirtilen iki farmakoforik grup kulla-
nılarak önceki çalışmamızda yapılan sentez prosedürüne göre tasarlanmış 
ve elde edilmiştir. Bütün sonuç bileşiklerinin antinosiseptif aktiviteleri in-
celenmiştir.
Yöntemler: Bileşiklerin yapıları 1H-NMR, 13C-NMR ve Kütle spektroskopi-
si gibi spektroskopik metodlarla aydınlatılmıştır. On adet sonuç bileşiği 
potansiyel in vivo antinosiseptif aktiviteleri sıcak taban ve asetik asitle in-
düklenmiş kıvranma testi kullanılarak araştırılmıştır. Ayrıca bu bileşiklerin 
potansiyel antikonvülzan aktiviteleri Pentilentetrazol (PTZ) ile uyarılmış 
nöbetlere karşı değerlendirilmiştir. Rota-Rod testi bileşiklerin muhtemel 
nörolojik hasarlarını incelemek amacıyla yapılmıştır. 
Bulgular: Serideki bileşiklerden hiçbiri sıcak tabaka testinde belirgin bir 
etki gösterememiştir. Bununla birlikte 2f bileşiği asetik asitle indüklenmiş 
kıvranma testinde 100 mg/kg dozla bileşiğin antinosiseptif etkisini göste-
ren bir biçimde kıvranma davranışının sayısında göze çarpan bir düşüşe 
neden olmuştur. Farelerin Rota-Rod gecikme süreleri test bileşikleri tara-
fından değiştirilememiştir. Ayrıca, test bileşikleri PTZ ile indüklenen nöbet 
testlerinde de etkisizdir.
Sonuç: Benziliden kalıntısı taşıyan 2f bileşiği en aktif türev olarak belirlendi.
Anahtar kelimeler: Antinosiseptif, hidrazon, imidazopirazin, sıcak taban testi, 
kıvranma testi
INTRODUCTION
The imidazo[1,2-a]pyrazine nucleus has been reported with a broad range of bioactivities, such as antimicrobial, antiviral, anticancer, 
antiulcer, anticonvulsant, anti-inflammatory, analgesic, and hypoglycemic activities (1-4). The heterocyclic ring system is also an analog 
ring of the imidazo[1,2-a]pyridine structure (5), which exists in the structure of the anticonvulsant drugs zolpidem, alpidem, and saripid-
em (6). Moreover, the imidazo[1,2-a]pyrazine derivative compounds have exhibited theophylline-like pharmacological properties, such 
as muscle relaxant, cardiotonic, and antibronchospasm activity, because of their similarity to the theophylline molecule, which includes 
an imidazo[1,2-a]pyrimidine ring in its structure (7-9). According to the literature (10), imidazo[1,2-a]pyrazine-3-(7H)-on derivative com-
pounds were designed as a prodrug of ibuprofen, which is a strong non-steroidal anti-inflammatory drug, and is reported to have a high 
anti-inflammatory activity. Furthermore, there are many studies regarding the effect of imidazopyrazines on the central nervous system 
(CNS) (11-13).
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Objective: The imidazopyrazine ring is a biologically active heterocyclic 
ring. Many hydrazide–hydrazone-possessing compounds have been re-
ported to have interesting bioactivity, such as antibacterial, antifungal, an-
ticonvulsant, anti-inflammatory, antituberculosis, and analgesic activities. 
In particular, aroyl hydrazides/hydrazone-containing hetero-rings, such as 
indole, pyridine, and imidazo[2,1-b]pyridine, and imidazo[1,2-a]pyrazine, 
have attracted special attention. We designed and synthesized N-(4-sub-
stitutedbenzylidene)imidazo[1,2-a]pyrazine-2-carbohydrazide (2a-j) deriv-
atives using the two aforementioned pharmacophoric units based on the 
synthetic procedure indicated in our previous study.
Methods: The structures of the compounds were elucidated using 1H-NMR, 
13C-NMR, and mass spectroscopy. Ten final compounds were screened for 
their possible in vivo antinociceptive activity using a hot plate and acetic 
acid-induced writhing tests. In addition, the potential anticonvulsant ac-
tivities of these compounds were evaluated using the PTZ-induced seizure 
test. A rotarod test was performed to examine probable neurological defi-
cits because of the test compounds.
Results: In the hot plate tests, none of the test compounds in the series 
demonstrated a significant effect. However, compound 2f, which was ad-
ministrated at 100 mg/kg, significantly decreased the number of writhing 
behaviors in the acetic acid-induced writhing tests, indicating the antino-
ciceptive activity of this compound. The rotarod latencies of mice were 
not changed by the test compounds. Furthermore, the tested compounds 
were ineffective in the PTZ-induced seizure tests.
Conclusion: Compound 2f bearing 5-benzylidene moiety was determined 
as the most active compound.
Keywords: Antinociceptive, hydrazone, imidazopyrazine, hot plate, writh-
ing test
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Hydrazone groups, which are derived from the carboxylic acid struc-
ture, have analgesic effects and have similar effects as carboxylic 
acid derivatives on CNS (14). Moreover, N-acylhydrazone has come 
to prominence and has acquired an important place in medicinal 
chemistry as an effective pharmacophoric group (15-17).
In this study, we designed and synthesized N’-(4-substitutedben-
zylidene)imidazo[1,2-a]pyrazine-2-carbohydrazide (2a-j) derivatives 
using the aforementioned two pharmacophoric units according 
to the synthetic procedure indicated. Ten final compounds were 
screened for their in vivo antinociceptive activity.
METHODS
General
The melting point (mp) was determined using the Electrothermal 
9100 digital melting point apparatus and were uncorrected. Spec-
troscopic data were recorded with the following instruments: IR, Shi-
madzu 8400S spectrophotometer (Shimadzu, Tokyo, Japan); 1H-NMR, 
Bruker 400 MHz spectrometer; 13C-NMR, Bruker 100 MHz spectrome-
ter; and MS-FAB VG Quattro Mass spectrometer.
General procedure for the synthesis of compounds
Imidazo[1,2-a]pyrazine-2-carboxylic acid hydrazides (1a, 1b):
A mixture of ethyl imidazo[1,2-a]pyrazine-2-carboxylate (0.1 mol) 
and hydrazine hydrate (0.2 mol) in ethanol was refluxed for 12 h. At 
the end of the reaction (observed by TLC), the mixture was cooled 
down, and the precipitated product was isolated by filtration to af-
ford the intermediate compounds 1a and 1b.
N’-(4-substitutedbenzylidene)-5-substitutedimidazo[1,2-a]
pyrazine-2-carbohydrazide (2a-2j):
Equimolar quantities of acid hydrazide intermediates (30 mmol) and 
various benzaldehydes in 30 mL ethanol were refluxed for 8–10 h. 
After TLC, the reaction mixture was cooled, and the solid precipitate 
was filtered and washed with ethanol.
N’-Benzylideneimidazo[1,2-a]pyrazine-2-carbohydrazide (2a)
Mp: 255°C (3)
N’-(4-Methylbenzylidene)imidazo[1,2-a]pyrazine-2-
carbohydrazide (2b)
Mp: 257 °C, Lit: 256–258°C (3).
N’-(4-Chlorobenzylidene)imidazo[1,2-a]pyrazine-2-carbohydrazide (2c)
Mp: 238°C (3).
N’-(4-Nitrobenzylidene)imidazo[1,2-a]pyrazine-2-carbohydrazide (2d)
Mp: 275°C (decomp) (3).
N’-(4-Cyanobenzylidene)imidazo[1,2-a]pyrazine-2-carbohydrazide (2e)
Yield: 74%, mp: 297°C (decomp). IR (cm−1): νmax 3215 (NH), 1659 
(C=O), 1602–1422 (C=N) and (C=C), and 1235–1015 (C-O). 1H-NMR 
(400 MHz, DMSO-d6) δ (ppm): 7.82–7.89 (4H, m, phenyl protons), 7.96 
(1H, d, J= 4.48 Hz, aromatic proton), 8.60–8.67 (3H, m, N=CH and aro-
matic protons), 9.15 (1H, s, aromatic proton), and 11.29 (1H, s, N-NH). 
13C-NMR (100 MHz, DMSO-d6, ppm): δ 111.92 (C), 117.01 (CH), 118.62 
(C), 120.76 (CH), 127.66 (2CH), 129.80 (C), 132.76 (2CH), 138.83 (C), 
139.33 (CH), 139.69 (C), 144.07 (CH), 146.58 (CH), and 158.22 (C). MS 
(FAB) (m/z): [M]+ 290. Anal. Calcd. for C15H10N6O: C, 62.06; H, 3.47; and 
N, 28.95. Found: C, 62.08; H, 3.48; and N, 28.94.
5-Bromo-N’-benzylidene-imidazo[1,2-a]pyrazine-2-carbohydrazide (2f)
Yield: 69 %. mp: 265°C (decomp). IR (cm−1): νmax 3210 (NH), 1662 (C=O), 
1603–1410 (C=N) and (C=C), and 1251–1018 (C-O). 1H-NMR (400 MHz, 
DMSO-d6) δ (ppm): 7.42–7.47 (3H, m, phenyl protons), 7.67–7.70 (2H, 
m, phenyl protons), 8.26 (1H, s, aromatic proton), 8.59 (2H, s, N=CH 
and aromatic protons), 9.18 (1H, s, aromatic proton), and 11.29 (1H, 
s, N-NH). 13C-NMR (100 MHz, DMSO-d6, ppm): δ 112.46 (C), 116.76 
(CH), 127.18 (2CH), 128.85 (2CH), 130.20 (CH), 131.75 (C), 134.27 
(CH), 139.94 (C), 140.11 (C), 142.35 (CH), 148.83 (CH), and 157.49 (C). 
MS (FAB) (m/z): [M]+ 358, [M+1]+ 359. Anal. Calcd. for C14H10BrN5O: C, 
48.86; H, 2.93; and N, 20.35. Found: C, 48.87; H, 2.92; and N, 20.34
5-Bromo-N’-(4-methylbenzylidene)imidazo[1,2-a]pyrazine-2- 
carbohydrazide (2g)
Yield: 68 %. mp: 271°C (decomp). IR (cm−1): νmax 3221 (NH), 1645 
(C=O), 1584–1442 (C=N) and (C=C), and 1247–1020 (C-O). 1H-NMR 
(400 MHz, DMSO-d6) δ (ppm): 2.31 (3H, s, CH3), 7.24 (2H, d, J = 8.02 Hz, 
phenyl protons), 7.58 (2H, d, J = 8.06 Hz, phenyl protons), 8.27 (1H, 
s, aromatic proton), 8.54 (1H, s, N=CH), 8.58 (1H, s, aromatic proton), 
9.17 (1H, s, aromatic proton), and 11.30 (1H, s, N-NH). 13C-NMR (100 
MHz, DMSO-d6, ppm): δ 21.05 (CH3), 112.46 (C), 116.70 (CH), 127.17 
(2CH), 129.47 (2CH), 131.57 (CH), 131.74 (C), 139.94 (C), 140.05 (C), 
140.19 (C), 142.33 (CH), 148.86 (CH), and 157.38 (C). MS (FAB) (m/z): 
[M]+ 358, [M+1]+ 359. Anal. Calcd. for C15H12BrN5O: C, 50.30; H, 3.38; 
and N, 19.55. Found: C, 50.31; H, 3.38; and N, 19.53.
5-Bromo-N’-(4-chlorobenzylidene)imidazo[1,2-a] 
pyrazine-2-carbohydrazide (2h)
Yield: 72 %. mp: 287°C (decomp). IR (cm−1): νmax 3222 (NH), 1642 (C=O), 
1603–1429 (C=N) and (C=C), and 1212–1054 (C-O). 1H-NMR (400 MHz, 
DMSO-d6) δ (ppm): 7.49 (2H, d, J = 8.48 Hz, phenyl protons), 7.70 (2H, 
d, J = 8.54 Hz, phenyl protons), 8.27 (1H, s, aromatic proton), 8.57 (1H, 
s, N=CH), 8.59 (1H, s, aromatic proton), 9.18 (1H, s, aromatic proton), 
and 11.29 (1H, s, N-NH). 13C-NMR (100 MHz, DMSO-d6, ppm): δ 112.47 
(C), 116.84 (CH), 128.81 (2CH), 128.98 (2CH), 131.78 (CH), 133.22 (C), 
134.63 (C), 139.96 (C), 140.00 (C), 142.37 (CH), 147.49 (CH), and 157.55 
(C). MS (FAB) (m/z): [M]+ 378, [M+1]+ 379, [M+2]+ 380. Anal. Calcd. for 
C14H9BrClN5O: C, 44.41; H, 2.40; and N, 18.50. Found: C, 44.41; H, 2.39; 
and N, 18.50.
5-Bromo-N’-(4-nitrobenzylidene)imidazo[1,2-a]pyrazine-2- 
carbohydrazide (2i)
Yield: 65 %. mp: 301°C (decomp). IR (cm−1): νmax 3217 (NH), 1654 
(C=O), 1603–1438 (C=N) and (C=C), and 1232–1019 (C-O). 1H-NMR 
(400 MHz, DMSO-d6) δ (ppm): 7.94 (2H, d, J = 8.80 Hz, phenyl protons), 
8.26-8.29 (3H, m, aromatic proton), 8.63 (1H, s, aromatic proton), 8.69 
(1H, s, N=CH), 9.19 (1H, s, aromatic proton), and 11.28 (1H, s, N-NH). 
13C-NMR (100 MHz, DMSO-d6, ppm): δ 112.45 (C), 116.62 (CH), 128.55 
(2CH), 128.18 (2CH), 130.98 (CH), 133.02 (C), 134.03 (C), 140.96 (C), 
142.09 (C), 142.49 (CH), 147.69 (CH), and 157.95 (C). MS (FAB) (m/z): 
[M]+ 389, [M+1]+ 390. Anal. Calcd. for C14H9BrN6O3: C, 43.21; H, 2.33; 
and N, 21.60. Found: C, 43.19; H, 2.35; and N, 21.58. 
5-Bromo-N’-(4-cyanobenzylidene)imidazo[1,2-a]pyrazine-2- 
carbohydrazide (2j)
Yield: 68 %. mp: 288°C (decomp). IR (cm−1): νmax 3220 (NH), 1661 
(C=O), 1598–1445 (C=N) and (C=C), and 1254–1023 (C-O). 1H-NMR 
(400 MHz, DMSO-d6) δ (ppm): 7.85 (2H, d, J = 8.90 Hz, phenyl pro-
tons), 7.88 (2H, d, J = 9.01 Hz, phenyl protons), 8.27 (1H, s, aromatic 
proton), 8.61 (1H, s, N=CH), 8.63 (1H, s, aromatic proton), 9.18 (1H, s, 
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aromatic proton), and 11.30 (1H, s, N-NH). MS (FAB) (m/z): [M]+ 369, 
[M+1]+ 370. Anal. Calcd. for C15H9BrN6O: C, 48.80; H, 2.46; and N, 22.76. 
Found: C, 48.79; H, 2.45; and N, 22.78. 13C-NMR (100 MHz, DMSO-d6, 
ppm): δ 112.27 (C), 116.54 (CH), 118.32 (C), 127.73 (2CH), 128.98 (C), 
132.80 (2CH), 138.72 (C), 134.63 (CH), 139.96 (C), 140.01 (C), 141.86 
(CH), 147.03 (CH), and 158.51 (C).
Pharmacology
Animals
Swiss albino mice, weighing 30 g to 40 g, were housed at a room 
temperature of 24+1°C with a 12/12-h light/dark cycle. The animals 
received only water 12 h before the experiments, because of the 
need to avoid food interference with absorption of the compounds. 
The experimental protocols that were used were approved by the 
Local Ethical Committee on Animal Experimentation of the Anadolu 
University, Eskişehir, Turkey. Informed consent is not required for this 
study.
Nociceptive tests
The compounds were screened to determine their antinociceptive 
activity profiles (n=6). The central component of nociception was 
projected from the hot plate test (18). Furthermore, the acetic acid–
induced writhing test was used to determine the potential antino-
ciceptive activity against chemical noxious stimulus (19). Diclofenac 
sodium (DCL) was used as the standard drug.
Behavioral tests
The rotarod test was performed (n=6) to examine the possible neuro-
logical deficits caused by the test compounds, which could give rise 
to false positives, such as muscle relaxant or impairment of the motor 
coordination (20).
To evaluate the presence of anticonvulsant activity, PTZ-induced sei-
zure tests were performed. PTZ at a dose of 80 mg/kg was applied 
to mice (n=10 in each group) to induce seizure (21). The time to the 
appearance of the first seizure (latency, min), percentage inhibition 
of convulsions, and percentage inhibition of death were recorded 
(22). Mice were observed over a period of 30 min; the absence of an 
episode of clonic spasm of at least a 5-s interval pointed out a com-
pound’s ability to abolish the effect of PTZ on seizure threshold, and 
these animals were thus accepted as protected (23).
Statistical analyses
The statistical analyses of the experimental data were determined by 
using GraphPad Prism 3.0 software (GraphPad Software, San Diego, 
CA, USA). One-way analysis of variance, followed by Tukey’s test were 
used to specify significant differences between the groups. The re-
sults were expressed as the mean±standard error of the mean (SEM). 
Differences between data sets were considered as significant when 
the p value was <0.05.
RESULTS
The present study was undertaken to synthesize ten imidazo[1,2-a]
pyrazine-2-carboxylic acid arylidenehydrazide derivatives and to 
investigate their potential antinociceptive activity. According to the 
synthetic procedure as indicated in figure 1, ethyl imidazo[1,2-a]pyr-
azine-2-carboxylate was used as the starting material. Imidazo[1,2-a]
pyrazine-2-carboxylic acid hydrazides were obtained by the reaction 
of the ester compound and hydrazine hydrate in ethanol under reflux 
conditions. The condensation of the hydrazides 1a and 1b with aro-
matic aldehydes in ethanol in the presence of catalytic amounts of 
acetic acid gained acylhydrazone derivatives of the final compounds 
(2a-j) in 64-74% yields. All the final compounds were well character-
ized by IR, 1H NMR, 13C NMR, and MS spectroscopic data. In the IR 
spectra of the final compounds, the significant stretching bands due 
to N-H, C=O, C-N and C-C, and C-O were at approximately 3225–3210 
cm−1, 1666–1642 cm−1, 1610–1422 cm−1, and 1254–1015 cm−1, re-
spectively. The 1H-NMR spectra data were also consistent with the 
assigned structures. In the 400-MHz 1H-NMR spectrum of the com-
pounds, protons of the imidazo[1,2-a]pyrazine ring were resonated 
much further downfield according to the phenyl protons, which 
Figure 1. The synthesis scheme of the compounds (2a-j)
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were approximately 8.26–9.19 ppm. In 13C-NMR, carbonyl carbon was 
assigned at about 158 ppm and the other carbons were seen at the 
estimated areas. In the mass spectra of compounds [M+1], the peaks 
were observed in agreement with their molecular formula.
According to the antinociceptive activity results, none of the test 
compounds in the series showed a significant antinociceptive effect 
in the hot plate tests (data not shown). On the other hand, compound 
2f (100 mg/kg) significantly (p<0.05) inhibited writhing behavior in 
the acetic acid–induced writhing tests (Figure 2). 
DISCUSSION
According to activity results, the reduction in the number of writhes 
after 2f treatment suggests that the mechanism of this compound 
may be related with a decrease in the release of inflammatory media-
tors in peripheral tissues or by direct blockage of its receptors, which 
results in an antinociceptive effect. Furthermore, this activity could 
be caused by an augmentation of the nociceptive threshold or by in-
terruption of the transmission of the pain stimulus to the nerve fiber.
In the rotarod tests, none of the tested compounds altered the la-
tency to fall from the rotating mill (data not shown), indicating that 
the observed antinociception in this study is unlikely to be caused by 
motor abnormalities.
In the PTZ-induced seizure tests, none of the tested compounds sig-
nificantly altered the onset of PTZ-induced tonic convulsions or pre-
vented the animals from PTZ-induced convulsions.
CONCLUSION
In this study, ten imidazo[1,2-a]pyrazine-2-carboxylic acid arylidene-
hydrazide derivatives (2a-j) have been synthesized and evaluated for 
their antinociceptive activity. Compound 2f bearing 5-benzylidene 
moiety was determined as the most active compound.
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